

## Literatura ACTA MEDICINAE 16/2025 Farmakologická léčba

- 2 **Stávající a do budoucna zvažované možnosti farmakoterapie obezity**  
MUDr. Martina Nováková, Ph.D. | prof. MUDr. Milan Kvapil, CSc., MBA Geriatrická interní klinika, 2. LF UK a FN Motol, Praha
- 2 **Současné možnosti léčby nadváhy a obezity**  
doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha
- 2 **Aktuální pohled na hormonální substituční terapii v léčbě klimakterického syndromu**  
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika, 2. LF UK a FN Motol; Katedra zdravotnických studií, Vysoká škola polytechnická, Jihlava  
PhDr. Vlasta Dvořáková, Ph.D. Katedra zdravotnických studií, Vysoká škola polytechnická, Jihlava
- 3 **P-glykoprotein, CYP3A4 a dostupnost pro centrální nervovou soustavu: co odlišuje abemaciclib od ostatních inhibitorů CDK4/6**  
doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha
- 3 **Novinky ve farmakologické léčbě plicní hypertenze**  
doc. MUDr. Radim Bečvář, CSc. Revmatologická klinika, 1. LF UK, Revmatologický ústav, Praha
- 4 **Vnímáme dostatečně odlišnosti inhalačních kortikosteroidů?**
- 4 **Příspěvek k rozsáhlé tematice léčby kortikosteroidy v respirační medicíně**  
doc. MUDr. Petr Čáp, Ph.D. Centrum alergologie a klinické imunologie, Nemocnice Na Homolce, Praha
- 4 **Aktuality v léčbě hemofilie**  
MUDr. Eva Drbohlavová Oddělení klinické hematologie, Krajská nemocnice Liberec, a. s.
- 4 **Aktuální pohledy na léčbu paroxysmální noční hemoglobinurie**  
MUDr. Libor Červinek, Ph.D. Interní hematologická a onkologická klinika, LF MU a FN Brno
- 5 **Chronické onemocnění ledvin – zaměřeno na IgA nefropatii**  
MUDr. Jan Vachek, MHA Klinika nefrologie, 1. LF UK a VFN Praha; Interní oddělení, Klatovská nemocnice, a. s.  
prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie, 1. LF UK a VFN Praha  
MUDr. Kateřina Oulehle, MBA Interní oddělení, Klatovská nemocnice, a. s.
- 5 **Aktualizované doporučené postupy KDIGO 2025 pro léčbu IgA nefropatie a IgA vaskulitidy: důraz na personalizovanou nefroprotektu a imunomodulaci**  
doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha
- 5 **Alzheimerova choroba**  
doc. MUDr. Roman Jiráček, CSc. Psychiatrická klinika, 1. LF UK a VFN Praha
- 6 **Stávající možnosti léčby amyotrofické laterální sklerózy a její výhledy**  
MUDr. Jana Mašková, Ph.D. Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN Praha
- 6 **Potenciál probiotik v léčbě psychiatrických onemocnění**  
PharmDr. Marek Lapka, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 6 **O čem se mluví v algeziologii**  
doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha
- 7 **Pomůže farmakogenetika snížit výskyt nežádoucích účinků léků?**  
Mgr. Hana Sládková Kavínová GHC Genetics, s. r. o., Praha
- 7 **Genomické testy jako nástroj racionální farmakoterapie v adjuvantní léčbě časného karcinomu prsu**  
doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha
- 7 **Terapeutický potenciál Ginkgo biloba: od mechanismu účinku po standardizaci produktů**  
PharmDr. Marek Lapka, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 8 **Superoxidovaný roztok kyseliny chlorné v léčbě ran: komplexní monografie se zvláštním důrazem na zdravotnický prostředek Aqvitox-D roztok a gel**  
doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

# Stávající a do budoucna zvažované možnosti farmakoterapie obezity

MUDr. Martina Nováková, Ph.D. | prof. MUDr. Milan Kvapil, CSc., MBA Geriatrická interní klinika, 2. LF UK a FN Motol, Praha

- 1 Dostupné z: <https://ct24.ceskatelevize.cz/clanek/veda/vedci-prisli-s-prekvapivou-teorii-o-vyznamu-pravekych-venusii-41504>, vyhledáno 9. 10. 2025.
- 2 Rosenblatt, M. B.: Pulmonary tuberculosis: evolution of modern therapy. *Bull NY Acad Med*, 1973, 49, s. 163–196.
- 3 Český statistický úřad: Zeměli – naděje dožití, příčiny smrti. Dostupné z: <https://csu.gov.cz/zemreli-nadeje-do-ziti-priciny-smrti>, vyhledáno 9. 10. 2025.
- 4 ÚZIS ČR: Tuberkulóza v České republice v roce 2020. Dostupné z: <https://www.uzis.cz/res/f/008358/tbc2020-cz.pdf>, vyhledáno 9. 10. 2025.
- 5 Look AHEAD Research Group: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med*, 2013, 369, s. 145–154.
- 6 van Veldhuisen, S. L. – Gorter, T. M. – van Woerden, G., et al.: Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. *Eur Heart J*, 2022, 43, s. 1955–1969.
- 7 Melson, E. – Ashraf, U. – Papamargaritis, D., et al.: What is the pipeline for future medications for obesity? *Int J Obes (Lond)*, 2025, 49, s. 433–451.
- 8 Wilding, J. P. H. – Batterham, R. L. – Calanna, S., et al.: STEP 1 Study Group: Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*, 2021, 384, s. 989–1002.
- 9 Garvey, W. T. – Batterham, R. L. – Bhatta, M., et al.: STEP 5 Study Group: Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat Med*, 2022, 28, s. 2083–2091.
- 10 Lincoff, A. M. – Brown-Frandsen, K. – Colhoun, H. M., et al.: SELECT Trial Investigators: Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*, 2023, 389, s. 2221–2232.
- 11 Jastreboff, A. M. – Aronne, L. J. – Ahmad, N. N., et al.: SURMOUNT-1 Investigators: Tirzepatide once weekly for the treatment of obesity. *N Engl J Med*, 2022, 387, s. 205–216.
- 12 Packer, M. – Zile, M. R. – Kramer, C. M., et al.: SUMMIT Trial Study Group: Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med*, 2025, 392, s. 427–437.
- 13 Ravussin, E. – Sanchez-Delgado, G. – Martin, C. K., et al.: Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. *Cell Metab*, 2025, 37, s. 1060–1074.e4.
- 14 Frias, J. P. – Hsia, S. – Eyde, S., et al.: Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. *Lancet*, 2023, 402, s. 472–483.
- 15 Pratt, E. – Ma, X. – Liu, R., et al.: Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. *Diabetes Obes Metab*, 2023, 25, s. 2634–2641.
- 16 Pratt, E.: Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. *Diabetes Obes Metab*, 2024, 26, s. 1137.
- 17 Karakasis, P. – Patoulias, D. – Pamporis, K., et al.: Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. *Metabolism*, 2023, 149, s. 155710.
- 18 Wharton, S. – Blevins, T. – Conroy, L., et al.: GZGI Investigators: Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. *N Engl J Med*, 2023, 389, s. 877–888.
- 19 Gogineni, P. – Melson, E. – Papamargaritis, D., et al.: Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? *Expert Opin Pharmacother*, 2024, 25, s. 801–818.
- 20 Davies, M. J. – Bajaj, H. S. – Broholm, C., et al.: REDEFINE 2 Study Group: Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. *N Engl J Med*, 2025, 393, s. 648–659.
- 21 Jastreboff, A. M. – Kaplan, L. M. – Frias, J. P., et al.: Retatrutide Phase 2 Obesity Trial Investigators: Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. *N Engl J Med*, 2023, 389, s. 514–526.
- 22 Gogineni, P. – Melson, E. – Papamargaritis, D., et al.: Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? *Expert Opin Pharmacother*, 2024, 25, s. 801–818.
- 23 Neary, N. M. – Small, C. J. – Druce, M. R., et al.: Peptide YY3-36 and glucagon-like peptide-1-36 inhibit food intake additively. *Endocrinology*, 2005, 146, s. 5120–5127.
- 24 Sloth, B. – Davidsen, L. – Holst, J. J., et al.: Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. *Am J Physiol Endocrinol Metab*, 2007, 293, s. E604–E609.
- 25 Batterham, R. L. – Cohen, M. A. – Ellis, S. M., et al.: Inhibition of food intake in obese subjects by peptide YY3-36. *N Engl J Med*, 2003, 349, s. 941–948.
- 26 Tan, T. M. M. – Minnion, J. – Khoo, B., et al.: Safety and efficacy of an extended-release peptide YY analogue for obesity: a randomized, placebo-controlled, phase 1 trial. *Diabetes Obes Metab*, 2021, 23, s. 1471–1483.
- 27 Dostupné z: [https://www.czso.cz/csu/czso/4017-06\\_-1919\\_2005-01](https://www.czso.cz/csu/czso/4017-06_-1919_2005-01), vyhledáno 9. 10. 2025.

## Současné možnosti léčby nadváhy a obezity

doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

- 1 Lingvay, I., et al.: Obesity in adults. *Lancet*, 2024, 404, s. 972–987.
- 2 O'Rahilly, S.: Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. *BMJ*, 1997, 314, s. 955–959.
- 3 Reaven, G.: Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. *Circulation*, 2002, 106, s. 286–288.
- 4 Reaven, G. – Abbasi, F. – McLaughlin, T.: Obesity, insulin resistance and cardiovascular disease. *Recent Prog Horm Res*, 2004, 59, s. 207–223.
- 5 Despres, J. P.: Cardiovascular disease under the influence of excess visceral fat. *Crit Pathw Cardiol*, 2007, 6, s. 51–59.
- 6 Dolinkova, M. – Dostalova, I. – Lacinova, Z., et al.: The endocrine profile of subcutaneous and visceral adipose tissue of obese patients. *Mol Cell Endocrinol*, 2008, 291, s. 63–70.
- 7 Bluher, M.: Adipose tissue dysfunction in obesity. *Exp Clin Endocrinol Diabetes*, 2009, 117, s. 241–250.
- 8 McNeely, W. – Benfield, P.: Orlistat. *Drugs*, 1998, 56, s. 241–249; discussion 250.
- 9 Greenway, F. L. – Dunayevich, E. – Tollefson, G., et al.: Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. *J Clin Endocrinol Metab*, 2009, 94, s. 4898–4906.
- 10 Pi-Sunyer, X. – Astrup, A. – Fujioka, K., et al.: A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med*, 2015, 373, s. 11–22.
- 11 Wilding, J. P. H. – Batterham, R. L. – Calanna, S., et al.: Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*, 2021, 384, s. 989–1002.
- 12 Lincoff, A. M. – Brown-Frandsen, K. – Colhoun, H. M.: Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*, 2023, 389, s. 2221–2232.
- 13 Coskun, T. – Sloop, K. W. – Loghin, C., et al.: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. *Mol Metab*, 2018, s. 3–14.
- 14 Willard, F. S. – Douros, J. D. – Gabe, M. B., et al.: Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. *JCI Insight*, 2020, 5, e140532.
- 15 Jastreboff, A. M. – le Roux, C. W. – Stefanski, A., et al.: SURMOUNT-1 Investigators: Tirzepatide for obesity treatment and diabetes prevention. *N Engl J Med*, 2025, 392, s. 958–971.
- 16 Aronne, L. J. – Sattar, N. – Horn, D. B., et al.: Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. *JAMA*, 2024, 331, s. 38–48.
- 17 Aronne, L. J. – Horn, D. B. – le Roux, C. W., et al.: Tirzepatide as compared with semaglutide for the treatment of obesity. *N Engl J Med*, 2025, 393, s. 26–36.

## Aktuální pohled na hormonální substituční terapii v léčbě klimakterického syndromu

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika, 2. LF UK a FN Motol; Katedra zdravotnických studií, Vysoká škola polytechnická, Jihlava

PhDr. Vlasta Dvořáková, Ph.D. Katedra zdravotnických studií, Vysoká škola polytechnická, Jihlava

- 1 The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause*, 2022, 29, s. 767–794, doi: 10.1097/GME.0000000000002028.
- 2 Santoro, N. – Epperson, C. N. – Mathews, S. B.: Menopausal symptoms and their management. *Endocrinol Metab Clin North Am*, 2015, 44, s. 497–515.
- 3 Biglia, N. – Cagnacci, A. – Gambacciani, M., et al.: Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? *Climacteric*, 2017, 20, s. 306–312.
- 4 Thurston, R. – Chang, Y. – Barinas-Mitchel, E., et al.: Physiologically assessed hot flashes and endothelial function among midlife women. *Menopause*, 2017, 24, s. 886–893.
- 5 Herber-Gast, B. – Brown, W. J. – Mishra, G. D.: Hot flashes and night sweats are associated with coronary heart disease risk in midlife: a longitudinal study. *BJOG*, 2015, 122, s. 1560–1567.
- 6 Thurston, R. C. – Aizenstein, H. J. – Derby, C. A., et al.: Menopausal hot flashes and white matter hyperintensities. *Menopause*, 2016, 23, s. 27–32.
- 7 Fait, T. – Vrablík, M.: Hormone replacement therapy (HRT) shortages for treating menopause: what can clinicians do to relieve symptoms and concerns? *Sci*, 2024, 6, s. 46.
- 8 Panay, N. – Anderson, R. A. – Nappi, R. E., et al.: Premature ovarian insufficiency: an International Menopause Society White Paper. *Climacteric*, 2020, 23, s. 426–446.
- 9 Fait, T.: Tibolon – jediný zástupce skupiny STEARS. *Čas Lék Čes*, 2019, 158, s. 107–111.
- 10 Scarabin, P. Y. – Oger, E. – Plu-Bureau, G.: Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. *Lancet*, 2003, 362, s. 428–432.
- 11 Hulley, S. – Grady, D. – Bush, T., et al.: Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA*, 1998, 280, s. 605–613.
- 12 Rossouw, J. E. – Anderson, G. L. – Prentice, R. L., et al.: Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*, 2002, 288, s. 321–333.
- 13 Koire, A. – Joffe, H. – Buckley, R.: Replacement in the prevention and treatment of cognitive decline, dementia, and cognitive dysfunction of depression. *Harv Rev Psychiatry*, 2022, 30, s. 215–222.
- 14 Kim, J. – Chang, J. H. – Jeong, M. J., et al.: A systematic review and metaanalysis of effects of menopause hormone therapy on cardiovascular diseases. *Sci Rep*, 2020, 10, 20631.
- 15 Fait, T. – Vrablík, M.: Coronary heart disease and hormone replacement therapy – from primary and secondary prevention to the window of opportunity. *Neuro Endocrinol Lett*, 2012, 33, suppl. 2, s. 17–21.
- 16 Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. *Lancet*, 1997, 350, s. 1047–1059.
- 17 Vinogradova, Y. – Coupland, C. – Hippisley-Cox, J.: Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using QResearch and CPRD databases. *BMJ*, 2020, 371, m3873.

- 18 Schairer, C. – Lubin, J. – Troisi, R., et al.: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA*, 2000, 283, s. 485–491.
- 19 Rossouw, J. E. – Anderson, G. L. – Prentice, R. L., et al.: Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *J Am Med Assoc*, 2002, 288, s. 321–333.
- 20 Anderson, G. L. – Limacher, M. – Assaf, A. R., et al.: The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *J Am Med Assoc*, 2004, 291, s. 1701–1712.
- 21 Bluming, A. Z. – Hodis, H. N. – Langer, R. D.: 'Tis but a scratch: a critical review of the Women's Health Initiative evidence associating menopausal hormone therapy with the risk of breast cancer. *Menopause*, 2023, 30, s. 1241–1245.
- 22 Rejnmark, L. – Vestergaard, P. – Tofteng, C. I., et al.: Response rates to oestrogen treatment in perimenopausal women: 5-year data from The Danish Osteoporosis Prevention Study (DOPS). *Maturitas*, 2004, 48, s. 307–320.
- 23 Fournier, A. – Mesrine, S. – Boutron-Ruault, M. C. – Clavel-Chapelon, F.: Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? *J Clin Oncol*, 2009, 27, s. 5138–5143.
- 24 Stute, P. – Wildt, L. – Neulen, J.: The impact of micronized progesterone on breast cancer risk: a systematic review. *Climacteric*, 2018, 21, s. 2, 111–122.
- 25 Abenhaim, H. A. – Suissa, S. – Azoulay, L., et al.: Menopausal hormone therapy formulation and breast cancer risk. *Obstet Gynecol*, 2022, 139, s. 1103–1110.
- 26 "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel: The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause*, 2022, 29, s. 767–794.
- 27 Ortman, O. – Beckermann, M. J. – Inwald, E. C., et al.: Peri- and postmenopause-diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short version. *Archi Gynecol Obstet*, 2020, 302, s. 763–777.
- 28 Tan, D. A. – Dayu, A. R. B.: Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. *Climacteric*, 2022, 25, s. 362–368.
- 29 Beral, V. – Banks, E. – Reeves, G.: Evidence from randomised trials on the long-term effects of HRT. *Lancet*, 2002, 360, s. 942–944.
- 30 Miller, J. – Chan, B. K. S. – Nelson, H. D.: Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. *Ann Intern Med*, 2002, 136, s. 680–690.
- 31 Wu, O.: Postmenopausal HRT and venous thromboembolism. *Gen Med*, 2005, 2, suppl. A, s. 18–27.
- 32 Scarabin, P. Y. – Oger, E. – Plu-Bureau, G.: Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. *Lancet*, 2003, 362, s. 428–432.
- 33 Straczek, C. – Oger, E. – Yon de Jonage-Canonica, M. B., et al.: Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. *Circulation*, 2005, 112, s. 3495–3500.
- 34 Fait, T. – Trnková, B. – Košťířová, M., et al.: Stanovení hladiny TFPI a jejich změny při estrogenní substituční terapii. *Čes Gynek*, 2007, 72, s. 343–347.
- 35 Renoux, C. – Dell Aniello, S. – Suissa, S.: Hormone replacement therapy and the risk of venous thromboembolism: a population based study. *J Thromb Haemost*, 2010, 8, s. 979–986.
- 36 Black, D.: The safety of oral versus transdermal estrogen. *Menopause*, 2020, 27, s. 1328–1329.
- 37 Tremollieres, F. – Brincat, M. – Erel, C. T., et al.: EMAS position statement: Managing menopausal women with a personal or family history of VTE. *Maturitas*, 2011, 69, s. 195–198.
- 38 Sturdee, D. W. – Pines, A.: Updated IMS recommendation on postmenopausal hormone therapy and preventive strategies for midlife health. *Climacteric*, 2011, 14, s. 302–320.
- 39 Stuenkel, C. A. – Davis, S. R. O. V. – Gompel, A., et al.: Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guidelines. *J Clin Endocrinol Metab*, 2015, 100, s. 3975–4011.
- 40 Hoibraaten, E. – Qvigstad, E. – Amesen, H., et al.: Increased risk in recurrent venous thromboembolism during HRT – results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVET). *Tromb Haemost*, 2000, 84, s. 961–966.
- 41 Lowe, G. – Woodward, M. – Vessey, M., et al.: Trombotic variables and risk of idiopathic venous thromboembolism in women aged 45–64 years. Relationships to HRT. *J Thromb Haemost*, 2000, 83, s. 530–535.
- 42 Olié, V. – Plu-Dureau, G. – Conard, J., et al.: Hormone therapy and venous thromboembolism among postmenopausal women. *Menopause*, 2011, 18, s. 488–493.
- 43 Canonico, M. – Oger, E. – Conard, J., et al.: Obesity and risk of venous thromboembolism among postmenopausal women: the differential impact of hormone therapy by route of administration. The ESTHER Study. *J Tromb Haemost*, 2006, 4, s. 1259–1265.
- 44 Sweetland, S. – Beral, V. – Balkwill, A., et al.: Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. *J Tromb Haemost*, 2012, 10, s. 2277–2286.
- 45 Vinogradova, Y. – Coupland, C. – Hippisley-Cox, J.: Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. *BMJ*, 2019, 364, k4810.

## P-glykoprotein, CYP3A4 a dostupnost pro centrální nervovou soustavu: co odlišuje abemaciclib od ostatních inhibitorů CDK4/6

doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

- 1 Clusan, L. – Ferrière, F. – Flouriot, G., et al.: A basic review on estrogen receptor signaling pathways in breast cancer. *Int J Mol Sci*, 2023, 24, s. 6834.
- 2 Shanabag, A. – Armand, J. – Son, E., et al.: Targeting CDK4/6 in breast cancer. *Exp Mol Med*, 2025, 57, s. 312–322.
- 3 Krupa, K. – Liszcz-Tymoszuk, A. – Czerw, N., et al.: CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—current treatment status. *Cancers*, 2025, 17, s. 1039.
- 4 McCartney, A. – Migliaccio, I. – Bonechi, M., et al.: Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice. *Front Oncol*, 2019, 9, s. 666.
- 5 Glaviano, A. – Wander, S. A. – Baird, R. D., et al.: Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. *Drug Resist Updat*, 2024, 76, s. 101103.
- 6 Gong, Y. – Li, H.: CDK7 in breast cancer: mechanisms of action and therapeutic potential. *Cell Commun Signal*, 2024, 22, s. 226.
- 7 Petrelli, F. – Ghidini, A. – Pedersini, R., et al.: Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. *Breast Cancer Res Treat*, 2019, 174, s. 597–604.
- 8 Gelbert, L. M. – Cai, S. – Lin, X., et al.: Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. *Invest New Drugs*, 2014, 32, s. 825–837.
- 9 Martorana, F. – Sanò, M. V. – Valerio, M. R., et al.: Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review. *Ther Adv Drug Saf*, 2024, 15, 20420986231224214.
- 10 Roncato, R. – Angelini, J. – Pani, A., et al.: CDK4/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions. *Int J Mol Sci*, 2020, 21, s. 6350.
- 11 Corona, S. P. – Generali, D.: Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. *Drug Des Devel Ther*, 2018, 12, s. 321–330.
- 12 Patnaik, A. – Rosen, L. S. – Tolaney, S. M., et al.: Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. *Cancer Discov*, 2016, 6, s. 740–753.
- 13 Jin, Y. – Xu, Z. – Yan, H., et al.: A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors. *Front Pharmacol*, 2020, 11, s. 891.
- 14 Chappell, J. C. – Chiang, A. Y. – Royalty, J., et al.: Abemaciclib does not increase the corrected QT interval in healthy participants. *Clin Transl Sci*, 2023, 16, s. 1617–1627.
- 15 Posada, M. M. – Morse, B. L. – Turner, P. K., et al.: Predicting clinical effects of CYP3A4 modulators on abemaciclib and active metabolites exposure using physiologically based pharmacokinetic modeling. *J Clin Pharmacol*, 2020, 60, s. 915–930.
- 16 Chappell, J. C. – Turner, P. K. – Pak, Y. A., et al.: Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate. *Clin Pharmacol Ther*, 2019, 105, s. 1187–1195.
- 17 Gebbia, V.: Abemaciclib in patients with end-stage renal disease and advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: a report of 2 cases. *Case Rep Oncol*, 2022, 15, s. 305–311.

## Novinky ve farmakologické léčbě plicní hypertenze

doc. MUDr. Radim Bečvář, CSc. Revmatologická klinika, 1. LF UK, Revmatologický ústav, Praha

- 1 Simonneau, G. – Montani, D. – Celermajer, D. S., et al.: Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J*, 2019, 53, 1801913.
- 2 Jansa, P. – Bečvář, R. – Ambrož, D., et al.: Výskyt a časná detekce plicní arteriální hypertenze u systémové sklerodermie v ČR. *Postgraduální medicína*, 2012, 14, příl. 1. Vybrané kapitoly z kardiologie, s. 42–48.
- 3 Jansa, P. – Jarkovský, J. – Al-Hiti, H., et al.: Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. *BMC Pulm Med*, 2014, 14, s. 45.
- 4 Humbert, M. – Kovacs, G. – Hoeper, M. M., et al.: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). *Eur Heart J*, 2022, 43, s. 3618–3731.
- 5 Jansa, P. – Ambrož, D. – Feščík, M., et al.: Současné možnosti léčby plicní arteriální hypertenze v České republice, její limity a perspektivy, aktualizace terapeutického algoritmu plicní arteriální hypertenze. Odborné stanovisko Pracovní skupiny plicní cirkulace České kardiologické společnosti. *Cor Vasa*, 2025, 67, s. 295–300.
- 6 Sommer, N. – Ghofrani, H. A. – Pak, O., et al.: Current and future treatments of pulmonary arterial hypertension. *Br J Pharmacol*, 2021, 178, s. 6–30.
- 7 Hoepfer, M. M. – Ewert, R. – Jansa, P., et al.: Randomized, multicenter study to assess the effects of different doses of sildenafil on mortality in adults with pulmonary arterial hypertension. *Circulation*, 2024, 149, s. 1949–1959.
- 8 Chin, K. M. – Gaine, S. P. – Gerges, C., et al.: Treatment algorithm for pulmonary arterial hypertension. *Eur Respir J*, 2024, 64, 2401325.
- 9 Ghofrani, H. A. – Galie, N. – Grimminger, F., et al.: PATENT-1 Study Group: Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J Med*, 2013, 369, s. 330–340.
- 10 Rubin, L. J. – Galie, N. – Grimminger, F., et al.: Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). *Eur Respir J*, 2015, 45, s. 1303–1313.
- 11 Guignabert, C. – Humbert, M.: Targeting transforming growth factor-β receptors in pulmonary hypertension. *Eur Respir J*, 2021, 57, 2002341.
- 12 Hoepfer, M. M. – Badesch, D. B. – Ghofrani, H. A., et al.: Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. *N Engl J Med*, 2023, 388, s. 1478–1490.
- 13 Humbert, M. – McLaughlin, V. V. – Badesch, D. B., et al.: ZENITH Trial Investigators: Sotatercept in patients with pulmonary arterial hypertension at high risk for death. *N Engl J Med*, 2025, 392, s. 1987–2000.
- 14 Grünig, E. – Jansa, P. – Fan, F., et al.: Randomized trial of macitentan/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. *J Am Coll Cardiol*, 2024, 83, s. 473–484.
- 15 ClinicalTrials.gov. A Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH). Identifier: NCT05147805.
- 16 ClinicalTrials.gov. Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD). Identifier: NCT05176951.
- 17 Frantz, R. P. – McLaughlin, V. V. – Sahay, S., et al.: TORREY Study Investigators: Serlutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Respir Med*, 2024, 12, s. 523–534.
- 18 ClinicalTrials.gov. Efficacy and Safety of Serlutinib in Adult Subjects With PAH (PROSERA). Identifier: NCT05934526.

- 19 Torres, F. – Farber, H. – Ristic, A., et al.: Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. *Eur Respir J*, 2019, 54, 1901030.
- 20 Humbert, M. – Hassoun, P. M. – Chin, K. M., et al.: MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study. *Eur Respir J*, 2024, 64, 2401110.
- 21 Saleh, S. – Mundry, T. – Nagelschmitz, J., et al.: Pharmacokinetics and lung deposition after administration of inhaled moslicigat (BAY 1237592): results from randomized phase I studies in healthy men. *Clin Pharmacokinet*, 2025, 64, s. 909–924.
- 22 ClinicalTrials.gov: Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc or SSc-associated Pulmonary Arterial Hypertension). Identifier: NCT02682511.
- 23 Hernández-Sánchez, J. – Harlow, L. – Church, C., et al.: Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. *Pulm Circ*, 2018, 8, 2045893217735820.

## Vnímáme dostatečně odlišnosti inhalačních kortikosteroidů? Příspěvek k rozsáhlé tematice léčby kortikosteroidy v respirační medicíně

doc. MUDr. Petr Čáp, Ph.D. Centrum alergologie a klinické imunologie, Nemocnice Na Homolce, Praha

- 1 Daley-Yates, P. T.: Inhaled corticosteroids: potency, dose equivalence and therapeutic index. *Br J Clin Pharmacol*, 2015, 80, s. 372–380.
- 2 Coleman, C. L. – Limone, B. – Sobieraj, D. M., et al.: Dosing frequency and medication adherence in chronic disease. *J Manag Care Pharm*, 2012, 18, s. 527–539.
- 3 Kulířová, M. – Sedláčková, V.: Současné možnosti biologické léčby bronchiálního astmatu. *Vnitřní Léč*, 2025, 71, s. 218–223.
- 4 Daley-Yates, P. – Brealey, N. – Thomas, S., et al.: Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. *Br J Clin Pharmacol*, 2021, 87, s. 483–493.
- 5 Hvidtfeldt, M. – Sverrild, A. – Pulga, A., et al.: Airway hyperresponsiveness reflects corticosteroid-sensitive mast cell involvement across asthma phenotypes. *J Allergy Clin Immunol*, 2023, 152, s. 107–116.e4.
- 6 Spahn, J. D. – Brightling, Ch. E. – O'Byrne, P. M., et al.: Effect of biologic therapies on airway hyperresponsiveness and allergic response: A systematic literature review. *J Asthma Allergy*, 2023, 16, s. 755–774.
- 7 Lipworth, B. – Kuo, R. W. – Stewart, K., et al.: Should airway hyperresponsiveness be included in the definition of clinical remission with biologic therapy in severe asthma? *J Allergy Clin Immunol Pract*, 2024, 12, s. 904–907.
- 8 Nielsen, L. P. – Dahl, R.: Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. *Am J Respir Crit Care Med*, 2000, 162, s. 2053–2057.
- 9 Shimizu, Y. – Shiobara, T. – Arai, R., et al.: Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma (RERACS study). *J Thorac Dis*, 2020, 12, s. 1877–1883.
- 10 Cho, E. Y. – Cho, J. E. – Jang, S. H., et al.: Real-world safety and effectiveness of fluticasone furoate/vilanterol in patients with asthma and/or chronic obstructive pulmonary disease. *Drug Saf*, 2023, 46, s. 951–960.
- 11 Valotis, A.: Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. *Resp Res*, 2007, 8, s. 54–62.
- 12 Salter, M. – Biggadike, K. – Matthews, J. L., et al.: Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. *Am J Physiol Lung Cell Mol Physiol*, 2007, 293, s. 660–667.
- 13 Kelly, H. W.: Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. *J Allergy Clin Immunol*, 1998, 102, s. 36–51.
- 14 Edsbäcker, S., et al.: In: Schleimer, R. P. – Busse, W. W. – O'Byrne, P. M., et al. (eds.): *Inhaled Glucocorticoids in Asthma*. New York, Marcel Dekker, Inc., 1997.
- 15 Derendorf, H. – Meltzer, E.: Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. *Allergy*, 2008, 63, s. 1292–1300.
- 16 Claxton, A. J. – Cramer, J. – Pierce, C., et al.: A systematic review of the associations between dose regimens and medication compliance. *Clin Ther*, 2001, 23, s. 1296–1310.
- 17 De Keyser, H. – Vuong, V. – Kaye, L., et al.: Is once versus twice daily dosing better for adherence in asthma and chronic obstructive pulmonary disease? *J Allergy Clin Immunol Pract*, 2023, 11, s. 2087–2093.

## Aktuality v léčbě hemofilie

MUDr. Eva Drbholavová Oddělení klinické hematologie, Krajská nemocnice Liberec, a. s.

- 1 von Drygalski, A. – Chowdhary, P. – Kulkarni, R., et al.: Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. *N Engl J Med*, 2023, 388, s. 310–318, doi: 10.1056/NEJMoa2209226.
- 2 Malec, L. – Peyvandji, F. – Chan, A. K. C., et al.: Efanesoctocog alfa prophylaxis for children with severe hemophilia A. *N Engl J Med*, 2024, 391, s. 235–246, doi: 10.1056/NEJMoa2312611.
- 3 Altuvost SPC.
- 4 Jiang, D. – Wang, M. – Wheeler, A. P., et al.: 2025 Clinical trials update on hemophilia, VWD, and rare inherited bleeding disorders. *AJH*, 2025, 100, s. 666–684, doi: 10.1002/ajh.27602.
- 5 Hermans, C. – Pierce, G. F.: Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine. *Res Pract Thromb Haemost*, 2023, 7, s. 100173, doi: 10.1016/j.rpth.2023.100173.
- 6 ISTH Washington 2025. Dostupné z: www.isthcongress.org/abstracts.
- 7 EHC Workshop on New Technologies in Rare Bleeding Disorders 2024. Dostupné z: www.ehc.eu/event/ehc-workshop-on-new-technologies-in-rare-bleeding-disorders-2024/, vyhledáno 17. 9. 2025.
- 8 Chowdhary, P. – Angchaisuksiri, P. – Apte, S., et al.: Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. *Lancet Haematol*, 2024, 11, s. e891–e904, doi: 10.1016/S2352-3026(24)00307-7.
- 9 Pasca, S.: Concizumab as a subcutaneous prophylactic treatment option for patients with hemophilia A or B: A review of the evidence and patient's perspectives. *J Blood Med*, 2022, 13, s. 191–199, doi: 10.2147/JBM.S242219.
- 10 Alhemo SPC.
- 11 Hympavzi SPC.
- 12 Qiftia SPC.
- 13 Pipe, S. W. – Lissitchkov, T. – Georgiev, P., et al.: Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B. *Blood Adv*, 2025, 9, s. 1147–1158, doi: 10.1182/bloodadvances.2024013900.
- 14 EAHAD Online – Gene Therapy in Haemophilia / Update on Durability in Gene Therapy.
- 15 Glasner, M. F. – Pipe, S. – Miesbach, W.: Gene-based therapies for hemophilia. *Res Pract Thromb Haemost*, 2025, 9, s. 102870, doi: 10.1016/j.rpth.2025.102870.
- 16 Pipe, S. W. – Leebeek, F. W. G. – Recht, M., et al.: Gene therapy with etranacogene dezaparvovec for hemophilia B. *N Engl J Med*, 2023, 388, s. 706–718, doi: 10.1056/NEJMoa2211644.
- 17 Ozelo, M. C. – Mahlangu, J. – Pasi, K. J., et al.: Valoctocogene roxaparvovec gene therapy for hemophilia A. *N Engl J Med*, 2022, 386, s. 1013–1025, doi: 10.1056/NEJMoa2113708.
- 18 Chowdhary, P. – Duran, B. – Batty, P., et al.: UKHDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults. *Haemophilia*, 2025, 31, s. 26–38, doi: 10.1111/hae.15125.
- 19 World Federation of Hemophilia: Shared Decision Making Tool. Dostupné z: https://sdm.wfh.org/, vyhledáno 17. 9. 2025.
- 20 Krumb, E. – Hermans, C.: Living with a "hemophilia-free mind" – The new ambition of hemophilia care? *Res Pract Thromb Haemost*, 2021, 5, e12567, doi: 10.1002/rth2.12567.
- 21 Laffan, M.: New products for the treatment of hemophilia. *Br J Haematol*, 2016, 172, s. 23–31, doi: 10.1111/bjh.13797.
- 22 Pipe, S. W.: New therapies for hemophilia. *Hematology Am Soc Hematol Educ Program*, 2016, 2016, s. 650–656, doi: 10.1182/asheducation-2016.1.650.
- 23 Hermans, C. – Pierce, G. F.: Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind. *J Thromb Haemost*, 2024, 22, s. 1844–1846, doi: 10.1016/j.jth.2024.04.010.
- 24 Weyand, A. C. – Malec, L. – Pipe, S. W.: Advances in haemophilia A and health equity: is it time to redefine severity? *Lancet Haematol*, 2024, 11, s. e90–e92, doi: 10.1016/S2352-3026(23)00270-3.
- 25 Wichaioy, S.: Advances in development of drug treatment for hemophilia with inhibitors. *ACS Pharmacol Transl Sci*, 2024, 7, s. 3795–3803, doi: 10.1021/acspci.4c00560.
- 26 Huntington, J. A. – Reckless, J. – Polderdijk, S. G. I., et al.: The preclinical profile of SerpinPC: a potential new treatment for hemophilia. *Blood Adv*, 2025, 9, s. 2402–2409, doi: 10.1182/bloodadvances.2024015201.
- 27 Teranishi-Ikawa, Y. – Soeda, T. – Koga, H., et al.: A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state. *J Thromb Haemost*, 2024, 22, s. 430–440, doi: 10.1016/j.jth.2023.09.034.
- 28 Ellsworth, P. – Ma, A.: Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? *Hematology Am Soc Hematol Educ Program*, 2021, 2021, s. 219–225, doi: 10.1182/hematology.2021000253.
- 29 Ay, C. – Frenzel, L. – Pinachyan, K. – Le Quellec, S.: Gene therapy for hemophilia A and B, from basic principles to clinical implementation: An illustrated review. *Haemophilia*, 2024, 30, s. 5–15, doi: 10.1111/hae.14907.
- 30 Arruda, V. R. – Doshi, B. S.: Gene therapy for hemophilia: facts and quandaries in the 21st century. *Mediter J Hematol Infect Dis*, 2020, 12, e2020069, doi: 10.4084/MJHID.2020.069.
- 31 Perrin, G. Q. – Herzog, R. W. – Markusic, D. M.: Update on clinical gene therapy for hemophilia. *Blood*, 2019, 133, s. 407–414, doi: 10.1182/blood-2018-07-820720.
- 32 Batty, P. – Lillicrap, D.: Hemophilia gene therapy: approaching the first licensed product. *Hemisphere*, 2021, 5, e540, doi: 10.1097/H59.0000000000000540.

## Aktuální pohledy na léčbu paroxysmální noční hemoglobinurie

MUDr. Libor Červinek, Ph.D. Interní hematologická a onkologická klinika, LF MU a FN Brno

- 1 Lee, J. W. – Sicre de Fontbrune, F. – Wong, L. L., et al.: Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. *Blood*, 2019, 133, s. 530–539.
- 2 Kulasekararaj, A. G. – Hill, A. – Rottinghaus, S. T., et al.: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood*, 2019, 133, s. 540–549.
- 3 Brodsky, R. A. – de Latour, R. P. – Rottinghaus, S. T., et al.: Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Americká společnost lidské genetiky (ASHG). *Hematologica*, 2021, 106, s. 230–237.
- 4 Bhak, R. H., et al.: Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. *Curr Med Res Opin*, 2021, 37, s. 1913–1923.
- 5 Hillmen, P. – Szer, J. – Weitz, I., et al.: Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. *N Engl J Med*, 2021, 384, s. 1028–1037.
- 6 Risitano, A.: Factor B inhibition with oral iptacopan monotherapy demonstrates sustained longterm efficacy and safety in anti C5 treated patients with paroxysmal nocturnal hemoglobinuria and persistent anemia: final 48-week results from multicenter phase III APPLY PNH Trial. *Blood*, 2023, 142 suppl. 1, s. 571–571.
- 7 DeLatour, R. P.: Clinical Breakthrough Hemolysis (BTH) during Monotherapy with the Oral Factor B Inhibitor Iptacopan Is Generally Not Severe and Managed without Treatment Discontinuation: 48-Week Data from the Phase III Apply-PNH and Appoint-PNH Trials in

- Paroxysmal Nocturnal Hemoglobinuria (PNH). *Blood*, 2023, 142, suppl. 1, s. 1338–1338.
- 8 **Notaro, R. – Luzzatto, L.**: Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. *N Engl J Med*, 2022, 387, s. 160–166.
- 9 **Kulasekararaj, A. – Mellor, J. – Earl, L., et al.**: PB2056: Prevalence of clinically significant extravascular hemolysis in stable C5 inhibitor-treated patients with PNH and its association with disease control, quality of life and treatment satisfaction. *Hemasphere*, 2023, 7, suppl., e35238f0.
- 10 **Risitano, A. M. – Kulasekararaj, A. G. – Lee, J. W., et al.**: Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. *Haematologica*, 2021, 106, s. 3188–3197.

## Chronické onemocnění ledvin – zaměřeno na IgA nefropatii

MUDr. Jan Vachek, MHA Klinika nefrologie, 1. LF UK a VFN Praha; Interní oddělení, Klatovská nemocnice, a. s.

prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie, 1. LF UK a VFN Praha

MUDr. Kateřina Oulehle, MBA Interní oddělení, Klatovská nemocnice, a. s.

- 1 **Duff, R. – Awofala, O. – Arshad M. T., et al.**: Global health inequalities of chronic kidney disease. *Nephrol Dial Transplant*, 2024, 39, s. 1692–1709, doi: 10.1093/ndt/gfae048.
- 2 StatPearls: Chronic Kidney Disease – Epidemiology and Causes. Online. Treasure Island (FL): StatPearls Publishing; 2024. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK535404/>, vyhledáno 20. 11. 2025
- 3 **Matoušovic, K. – Rossman, P. – Skibová, J., et al.**: IgA nefropatie. Morfologie, klinický obraz a význam mesangálních uloženin fibrinoidu. *Čas Lék Čes*, 1992, 131, s. 174–177.
- 4 **Gentile, M. – Sanchez-Russo, L. – Riella, L. V., et al.**: Immune abnormalities in IgA nephropathy. *Kidney Int*, 2023, 16, s. 1059–1070, doi: 10.1093/ckj/sfad025.
- 5 **Coppo, R.**: IgA nephropathy: Update on pathogenesis and treatment. *Cleve Clin J Med*, 2025, 92, s. 373–380, doi:10.3949/ccjm.92a.23039.
- 6 **Monteiro, R. C. – Yao, K.**: Is there a role for gut microbiome dysbiosis in IgA nephropathy? *Front Immunol*, 2022, 13, 856382, doi: 10.3389/fimmu.2022.856382.
- 7 **Gesualdo, L. – Di Leo, V. – Coppo, R.**: The mucosal immune system and IgA nephropathy. *Semin Immunopathol*, 2021, 43, s. 657–668, doi: 10.1007/s00281-021-00871-y.
- 8 **Kataoka, H. – Manabe, S. – Moriyama, T., et al.**: Attribute-based medicine for IgA nephropathy: risk factor constellations influence kidney prognosis. *Nephrol Dial Transplant*, 2025, gfa170, doi: 10.1093/ndt/gfa170.
- 9 **Perkovic, V. – Barratt, J. – Rovin, B., et al.**: APPLAUSE-IgAN Investigators: Alternative complement pathway inhibition with iptacopan in IgA nephropathy. *N Engl J Med*, 2025, 392, s. 531–543, doi: 10.1056/NEJMoa2410316.
- 10 **Heerspink, H. J. L. – Jardine, M. – Kohan, D. E., et al.**: ALIGN Study Investigators: Atrasentan in patients with IgA nephropathy. *N Engl J Med*, 2025, 392, s. 544–554.
- 11 **Perkovic, V. – Barratt, J. – Rovin, B., et al.**: Alternative complement pathway inhibition with iptacopan in IgA nephropathy. *N Engl J Med*, 2025, 392, s. 531–543, doi: 10.1056/NEJMoa2410316.
- 12 **Lafayette, R. – Kristensen, J. – Stone, A., et al.**: Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial. *Lancet*, 2023, 402, s. 859–870, doi: 10.1016/S0140-6736(23)01554-4.
- 13 **Zhang, Y. – Hu, Y. T. – Lv, J. C., et al.**: Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial. *Pediatr Nephrol*, 2023, 38, s. 3211–3220, doi: 10.1007/s00467-023-05919-9.
- 14 **Tesař, V.**: SGLT2 inhibitors in non-diabetic kidney disease. *Adv Clin Exp Med*, 2022, 31, s. 105–107, doi: 10.17219/acem/145734.
- 15 **Wheeler, D. C. – Toto, R. D. – Stefánsson, B. V., et al.**: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. *Kidney Int*, 2021, 100, s. 215–224, doi: 10.1016/j.kint.2021.03.033.
- 16 **Pitcher, D. – Braddon, F. – Hendry, B., et al.**: Long-term outcomes in IgA nephropathy. *Clin J Am Soc Nephrol*, 2023, 18, s. 727–738, doi: 10.2215/CJN.000000000000135.
- 17 **Novartis: Fabhalta (iptacopan) meets phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN).** Online. Dostupné z: <https://www.novartis.com/news/media-releases/novartis-fabhalta-iptacopan-meets-phase-iii-primary-endpoint-slows-kidney-function-decline-patients-iga-nephropathy>, vyhledáno 20. 11. 2025.
- 18 **Ramsawak, S. – Cohen, S. – Linares, A., et al.**: IgA nephropathy: Update on pathogenesis and treatment. *Cleve Clin J Med*, 2025, 92, s. 373–383, doi: 10.3949/ccjm.92a.24105.

## Aktualizované doporučené postupy KDIGO 2025 pro léčbu IgA nefropatie a IgA vaskulitidy: důraz na personalizovanou nefroprotektici a imunomodulaci

doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

- 1 **Wyatt, R. J. – Julian, B. A.**: IgA nephropathy. *N Engl J Med*, 2013, 368, s. 2402–2414.
- 2 **Li, L. S. – Liu, Z. H.**: Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. *Kidney Int*, 2004, 66, s. 920–923.
- 3 **Crowley-Nowick, P. A. – Julian, B. A. – Wyatt, R. J., et al.**: IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course. *Kidney Int*, 2011, 39, s. 1218–1224.
- 4 **O’Shaughnessy, M. M. – Hogan, S. L. – Thompson, B. D., et al.**: Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. *Nephrol Dial Transplant*, 2018, 33, s. 661–669.
- 5 **Pitcher, D. – Braddon, F. – Hendry, B., et al.**: Long-term outcomes in IgA nephropathy. *Clin J Am Soc Nephrol*, 2023, 18, s. 727–738.
- 6 **Bharati, J. – Jhaveri, K. D.**: Prognosis of IgA nephropathy: a lifetime story. *Clin J Am Soc Nephrol*, 2023, 18, s. 699–701.
- 7 **KDIGO 2025 IgA Nephropathy (IgAN) / IgA Vasculitis (IgAV).** Dostupné z: <https://kdigo.org/guidelines/iga-nephropathy>, vyhledáno 13. 11. 2025.
- 8 **Barratt, J. – Rovin, B. H. – Cattran, D., et al.**: Why target the gut to treat IgA nephropathy? *Kidney Int Rep*, 2020, 5, s. 1620–1624.
- 9 **Barratt, J. – Kristensen, J. – Pedersen, C., et al.**: Insights on Nefecon, a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy. *Drug Des Devel Ther*, 2024, 18, s. 3415–3428.
- 10 **Lafayette, R. – Kristensen, J. – Stone, A., et al.**: Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial. *Lancet*, 2023, 402, s. 859–870.
- 11 **Barratt, J. – Lafayette, R. – Kristensen, J., et al.**: Results from part A of the multi-center, double-blind, randomized, placebo-controlled NeflgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. *Kidney Int*, 2023, 103, s. 391–402.
- 12 **Rovin, B. H. – Barratt, J. – Heerspink, H. J. L., et al.**: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. *Lancet*, 2023, 402, s. 2077–2090.

## Alzheimerova choroba

doc. MUDr. Roman Jiráček, CSc. Psychiatrická klinika, 1. LF UK a VFN Praha

- 1 **Boess, F. G. – Scelsi, M. A. – Grimmer, T., et al.**: At-home administration of gantenerumab by care partners to people with early Alzheimer’s disease: feasibility, safety and pharmacodynamic impact. *The Journal of Prevention of Alzheimer’s Disease*, 2024, 11, s. 537–548, doi: 10.14283/jpad.2024.60.
- 2 **Bougea, A. – Debasa-Mouce, M. – Gulkarov, S., et al.**: From better diagnostics to earlier treatment: the rapidly evolving Alzheimer’s disease landscape. *Medicina*, 2025, 61, s. 1462.
- 3 **Che, P. – Cai, L. – Yiu, F. – Wang, Y.**: Cerebral perfusion is correlated with cerebral metabolism and amyloid deposition in Alzheimer’s disease. *Transl Psychiatry*, 2025, 15, s. 189.
- 4 **Daly, T. – Olluri, A. – Kurkinen, M.**: Anti-amyloid treatment in Alzheimer’s disease: evidence and ethics. *Advances in Clinical and Experimental Medicine*, 2024, 33, s. 1303–1309, doi: 10.17219/acem/198674.
- 5 **Davidson, M. – Stanciu, G. D. – Rabinowitz, J., et al.**: Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer’s disease comorbidities? *Dialogues in Clinical Neuroscience*, 2025, 27, s. 1–12.
- 6 **Filho, C. E. C. – Loss, L. B. – Marcolongo-Pereira, C., et al.**: Advances in Alzheimer’s disease’s pharmacological treatment. *Frontiers in Pharmacology*, 2023, 14, 1101452, doi: 10.3389/fphar.2023.1101452.
- 7 **Gueorguieva, I. – Chow, K. – Chua, L., et al.**: Donanemab exposure-response in early symptomatic Alzheimer’s disease. *Alzheimer’s Dement*, 2025, 21, s. 890–903, doi: 10.1002/alz.13491.
- 8 **Jiráček, R. a kol.**: *Gerontopsychiatrie*. Galén, Praha, 2013.
- 9 **Korábečný, J. – Soukup, O. – Vališ, M., et al.**: *Alzheimerova nemoc*. Maxdorf, Praha, 2020.
- 10 **Paczynski, M. – Hofmann, A. – Snider, B. J., et al.**: Lecanemab treatment in a specialty memory clinic. *JAMA*, 2025, 82, s. 637–646, doi: 10.1001/jamaneurol.2025.1232.
- 11 **Vyhňálek, M. – Vyhňálková, E. – Laczó, J.**: Genetika Alzheimerovy nemoci pro klinickou praxi. *Neurologie pro praxi*, 2019, 20, s. 352–355.
- 12 **Yao, R. – Ouyang, Z. – Xu, T. – Zhu, Y.**: Immune system-associated genes in patients with Alzheimer’s disease. *J Alzheimers Dis*, 2025, 98, s. 825–835, doi: 10.3233/JAD-250364.
- 13 **Untu, I. – Davidson, M. – Stanciu, G. D., et al.**: Neurobiological and therapeutic landmarks of depression associated with Alzheimer’s disease dementia. *Frontiers in Aging Neuroscience*, 2025, 17, 1584607.
- 14 **Yoo, J. – Lee, J. – Ahn, B., et al.**: Multi-target-directed therapeutic strategies for Alzheimer’s disease: controlling amyloid- $\beta$  aggregation, metal ion homeostasis, and enzyme inhibition. *Chemical Science*, 2015, 6, s. 2015–2035.
- 15 **Zhang, J. – Zhang, Y. – Wang, J., et al.**: Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. *Signal Transduction and Targeted Therapy*, 2024, 9, s. 211, doi: 10.1038/s41392-024-01911-3.
- 16 **Zvěřová, M., et al.**: *Vybrané kapitoly z gerontopsychiatrie*. Grada, Praha, 2022.

# Stávající možnosti léčby amyotrofické laterální sklerózy a její výhledy

MUDr. Jana Mašková, Ph.D. Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN Praha

- 1 Van Damme, P. et al.: European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). *European Journal of Neurology*, 2024, 31, e16264.
- 2 Masrori, P. – Van Damme, P.: Amyotrophic lateral sclerosis: a clinical review. *Eur J Neurol*, 2020, 27, s. 1918–1929.
- 3 Longinetti, E. – Fang, F.: Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. *Current Opinion in Neurology*, 2019, 32, s. 771–776, doi: 10.1097/WCO.000000000000073.
- 4 McAlary, L. – Yerbury, J. J. – Cashman, N. R.: The prion-like nature of amyotrophic lateral sclerosis. *Prog Mol Biol Transl Sci*, 2020, 175, s. 261–296.
- 5 Taylor, J. P. – Brown, R. H., Jr. – Cleveland, D. W.: Decoding ALS: from genes to mechanism. *Nature*, 2016, 539, s. 197–206.
- 6 Doble, A.: The pharmacology and mechanism of action of riluzole. *Neurology*, 1996, 47, suppl. 4, s. S233–S241.
- 7 Bellingham, M. C.: A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? *CNS Neurosci Ther*, 2011, 17, s. 4–31.
- 8 Bensimon, G. – Lacomblez, L. – Meininger, V.: ALS/Riluzole Study Group: A controlled trial of riluzole in amyotrophic lateral sclerosis. *N Engl J Med*, 1994, 330, s. 585–591.
- 9 Andrews, J. A. – Jackson, J. E. – Heiman-Patterson, T. D., et al.: Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener*, 2020, 21, s. 509–518, doi: 10.1080/21678421.2020.1771734.
- 10 Kawano, C. – Isozaki, Y. – Nakagawa, A., et al.: Liver injury risk factors in amyotrophic lateral sclerosis patients treated with riluzole. *Yakugaku Zasshi*, 2020, 140, s. 923–928.
- 11 Berdyski, M. – Miszta, P. – Safranow, K., et al.: SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. *Sci Rep*, 2022, 12, s. 103.
- 12 Blair, H. A.: Tofersen: first approval. *Drugs*, 2023, 83, s. 1039–1043.
- 13 Miller, T. M. – Cudkovic, M. E. – Genge, A., et al.: Trial of antisense oligonucleotide tofersen for SOD1 ALS. *N Engl J Med*, 2022, 387, s. 1099–1110.
- 14 Benatar, M. – Wu, J. – Andersen, P. M., et al.: Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. *Neurotherapeutics*, 2022, 19, s. 1248–1258.
- 15 McGuigan, A. – Blair, H. A.: Tofersen: a review in amyotrophic lateral sclerosis associated with SOD1 mutations. *CNS Drugs*, 2025, 39, s. 903–912.
- 16 Cruz, M. P.: Edo-rivastigmine (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. *PT*, 2018, 43, s. 25–28.
- 17 Writing Group; ALS Study Group: Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. *Lancet Neurol*, 2017, 16, s. 505–512.
- 18 Brooks, B. R. – Berry, J. D. – Ciepiewska, M., et al.: Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis. *E Clinical Medicine*, 2022, 52, 101590.
- 19 Brooks, B. R. – Pioro, E. P. – Sakata, T., et al.: The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis. *Muscle Nerve*, 2023, 68, s. 397–403.
- 20 Witzel, S. – Maier, A. – Steinbach, R., et al.: Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. *JAMA Neurology*, 2022, 79, s. 121–130.
- 21 Abdul Wahid, S. F. – Law, Z. K. – Ismail, N. A., et al.: Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. *Cochrane Database Syst Rev*, 2019, 12, CD011742.
- 22 Seif El Dahan, K. – Daher, D. – Singal, A. G., et al.: Multidisciplinary care for patients with HCC: a systematic review and meta-analysis. *Hepatal Commun*, 2023, 7, e0249.
- 23 The Lancet Neurology: Multidisciplinary care for amyotrophic lateral sclerosis. *Lancet Neurol*, 2024, 23, s. 649.
- 24 Sales de Campos, P. – Olsen, W. L. – Wymer, J. P., et al.: Respiratory therapies for amyotrophic lateral sclerosis: a state of the art review. *Chron Respir Dis*, 2023, 20, 14799731231175915.
- 25 Sousa-Catita, D. – Mascarenhas, P. – Oliveira, C., et al.: Nutrition and survival of 150 endoscopic gastrostomy-fed patients with amyotrophic lateral sclerosis. *Nutrients*, 2025, 17, s. 1292.
- 26 Mercadante, S. – Al-Husaini, L.: Palliative care in amyotrophic lateral sclerosis. *J Pain Symptom Manage*, 2023, 66, s. e485–e499.

## Potenciál probiotik v léčbě psychiatrických onemocnění

PharmDr. Marek Lapka, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 *The Lancet Global Health*. Mental health matters. *Lancet Glob Health*, 2020, 8, e1352.
- 2 Cryan, J. F. – O’Riordan, K. J. – Sandhu, K., et al.: The gut microbiome in neurological disorders. *Lancet Neurol*, 2020, 19, s. 179–194.
- 3 Rajoka, M. S. R. – Mehresh, H. M. – Kitazawa, H., et al.: Techno-functional properties and immunomodulatory potential of exopolysaccharide from *Lactiplantibacillus plantarum* MM89 isolated from human breast milk. *Food Chem*, 2022, 377, s. 131954.
- 4 Caso, J. R. – MacDowell, K. S. – González-Pinto, A., et al.: Gut microbiota, innate immune pathways, and inflammatory control mechanisms in patients with major depressive disorder. *Transl Psychiatry*, 2021, 11, 645.
- 5 Carding, S. – Verbeke, K. – Vipond, D. T., et al.: Dysbiosis of the gut microbiota in disease. *Microb Ecol Health Dis*, 2015, 26, 26191.
- 6 Wang, H. – Lee, I. S. – Braun, C., et al.: Effect of probiotics on central nervous system functions in animals and humans: a systematic review. *J Neurogastroenterol Motil*, 2016, 22, s. 589–605.
- 7 Bagga, D. – Aigner, C. S. – Reichert, J. L., et al.: Influence of 4-week multi-strain probiotic administration on resting-state functional connectivity in healthy volunteers. *Eur J Nutr*, 2019, 58, s. 1821–1827.
- 8 Bagga, D. – Reichert, J. L. – Koschutnig, K. A., et al.: Probiotics drive gut microbiome triggering emotional brain signatures. *Gut Microbes*, 2018, 9, s. 486–496.
- 9 Papalini, S. – Michels, F. – Kohn, N., et al.: Stress matters: Randomized controlled trial on the effect of probiotics on neurocognition. *Neurobiol Stress*, 2019, 10, 100141.
- 10 Tillisch, K. – Labus, J. – Kilpatrick, L., et al.: Consumption of fermented milk product with probiotic modulates brain activity. *Gastroenterology*, 2013, 144, s. 1394–401, 1401.e1-4.
- 11 Wang, H. – Braun, C. – Murphy, E. F., et al.: Bifidobacterium longum 1714TM strain modulates brain activity of healthy volunteers during social stress. *Am J Gastroenterol*, 2019, 114, s. 1152–1162.
- 12 Pinto-Sanchez, M. L. – Hall, G. B. – Ghajjar, K., et al.: Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. *Gastroenterol*, 2017, 153, s. 448–459.e8.
- 13 Naseribafrouei, A. – Hestad, K. – Avershina, E., et al.: Correlation between the human fecal microbiota and depression. *Neurogastroenterology Motil*, 2014, 26, s. 1155–1162.
- 14 Pirbaglou, M. – Katz, J. – de Souza, R. J., et al.: Probiotic supplementation can positively affect anxiety and depressive symptoms: a systematic review of randomized controlled trials. *Nutr Res*, 2016, 36, s. 889–898.
- 15 Ng, Q. X. – Peters, C. – Ho, C. Y. X., et al.: A meta-analysis of the use of probiotics to alleviate depressive symptoms. *J Affect Disord*, 2018, 228, s. 13–19.
- 16 Akkash, G. – Kashani-Poor, Z. – Tajabadi-Ebrahimi, M., et al.: Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. *Nutr*, 2016, 32, s. 315–320.
- 17 Kazemi, A. – Noorbala, A. A. – Azam, K., et al.: Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. *Clin Nutr*, 2019, 38, s. 522–528.
- 18 Majeed, M. – Nagabushan, K. – Arumugam, S., et al.: Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomized, double-blind, placebo controlled, multi-centre, pilot clinical study. *Food Nutr Res*, 2018, 62.
- 19 Ho, Y.-T. – Tsai, Y.-Ch. – Kuo, T. B. J., et al.: Effects of lactobacillus plantarum PS128 on depressive symptoms and sleep quality in self-reported insomnia: a randomized, double-blind, placebo-controlled pilot trial. *Nutrients*, 2021, 13, 2820.
- 20 Reininghaus, E. Z. – Platzer, M. – Kohlhammer-Dohr, A., et al.: PRO-VIT: Supplementary probiotic treatment and vitamin B7 in depression – a randomized controlled trial. *Nutrients*, 2020, 12, 3422.
- 21 Reis, D. J. – Ilardi, S. S. – Punt, S. E. W.: The anxiolytic effect of probiotics: A systematic review and meta-analysis of the clinical and pre-clinical literature. *PLoS ONE*, 2018, 13, e0199041.
- 22 Eskandarzadeh, S. – Effatpanah, M. – Khosravi-Darani, K., et al.: Efficacy of a multispecies probiotic as adjunctive therapy in generalized anxiety disorder: a double blind, randomized, placebo-controlled trial. *Nutr Neurosci*, 2021, 24, s. 102–108.
- 23 Adikari, A. M. G. C. P. – Appukutty, M. – Kuan, G.: Effects of daily probiotics supplementation on anxiety induced physiological parameters among competitive football players. *Nutrients*, 2020, 12, 1920.
- 24 Dickerson, F. – Severance, E. – Yolken, R.: The microbiome, immunity, and schizophrenia and bipolar disorder. *Brain Behav Immun*, 2017, 62, s. 46–52.
- 25 Ghaderi, A. – Banafshe, H. R. – Mirhosseini, N., et al.: Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. *BMC Psychiatry*, 2019, 19, 77.
- 26 Cusotto, S. – Clarke, G. – Dinan, T. G., et al.: Psychotropics and the microbiome: a chamber of secrets... *Psychopharmacology*, 2019, 236, s. 1411–1432.

## O čem se mluví v algeziologii

doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

- 1 Keam, S. J.: Suzetrigine: first approval. *Drugs*, 2025, 85, s. 845–851.
- 2 Hu, S. – Lyu, D. – Gao, J.: Suzetrigine: The first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain. *Drug Discov Ther*, 2025, 19, s. 80–82.
- 3 Bertoch, T. – D’Aunno, D. – McCoun, J., et al.: Suzetrigine, a nonopioid Nav1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. *Anesthesiology*, 2025, 142, s. 1085–1099.
- 4 Stewart, M. J. – Weaver, L. M. – Ding, K., et al.: Analgesic effects of a highly selective mPGES-1 inhibitor. *Sci Rep*, 2023, 13, s. 3326.
- 5 Jiang, X. – Renkema, H. – Pennings, B., et al.: Mechanism of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-1-mediated PGE2 biosynthesis by sonlicromanol’s metabolite KH176m. *Sci Rep*, 2021, 11, s. 880.
- 6 Ding, K. – Zhou, Z. – Hou, S.: Structure-based discovery of mPGES-1 inhibitors suitable for preclinical testing in wild-type mice as a new generation of anti-inflammatory drugs. *Sci Rep*, 2018, 8, s. 5205.
- 7 Edenius, C. – Ekström, G. – Stenberg, R. – Tornling, G.: O-195 Vipoglanstat, an oral non-hormonal treatment in clinical development for endometriosis. *Human Reproduction*, 2025, 40, suppl. 1, deaf097.195.
- 8 Ledford, H.: How understudied endometriosis causes pain for hundreds of millions of women. *Nature*, 2024, doi: 10.1038/d41586-024-03628-3.
- 9 Iwane, S. – Nemoto, W. – Miyamoto, T., et al.: Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy. *Sci Rep*, 2024, 14, s. 1039.
- 10 Rice, A. S. C. – Dworkin, R. H. – Finnerup, N. B., et al.: Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. *Pain*, 2021, 162, s. 2578–2589.
- 11 Zamanillo, D. – Romero, L. – Merlos, M. – Vela, J. M.: Sigma 1 receptor: a new therapeutic target for pain. *Eur J Pharmacol*, 2013, 716, s. 78–93.
- 12 Bruna, J. – Videla, S. – Argryriou, A. A., et al.: Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: a randomized, double-blind, placebo-controlled phase IIa clinical trial. *Neurotherapeutics*, 2018, 15, s. 178–189.
- 13 Gálvez, R. – Mayoral, V. – Cebrecos, J., et al.: E-52862—a selective sigma-1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double-blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy. *Eur J Pain*, 2025, 29, s. e4755.

# Pomůžte farmakogenetika snížit výskyt nežádoucích účinků léků?

Mgr. Hana Sládková Kavínová GHC Genetics, s. r. o., Praha

- World Health Organization: Patient Safety. Dostupné z: <https://www.who.int/news-room/fact-sheets/detail/patient-safety>, vyhledáno 14. 11. 2025.
- Chenchula, S. – Atal, S. – Uppugunduri, C. R. S.: A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care. *Pharmacogenomics J*, 2024, 9, doi: 10.1038/s41397-024-00326-1.
- Swen, J. J. – van der Wouden, C. H. – Manson, L. E., et al.: A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomized crossover implementation study. *Lancet*, 2023, 401, s. 347–356, doi: 10.1016/S0140-6736(22)01841-4.
- ClinPGx: Allele Frequency. Dostupné z: <https://www.clinpgx.org/alleleFrequency>, vyhledáno 14. 11. 2025.
- Elliott, L. S. – Henderson, J. C. – Neradilek, M. B., et al.: Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. *PLoS One*, 2017, 12, e0170905, doi: 10.1371/journal.pone.0170905.
- Bénard-Larivière, A. – Miremont-Salamé, G. – Pérault-Pochat, M. C., et al.: Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study. *Fundam Clin Pharmacol*, 2015, 29, s. 106–111.
- Van Driest, S. L. – Shi, Y. – Bowton, E. A., et al.: Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. *Clin Pharmacol Ther*, 2014, 95, s. 423–431, doi: 10.1038/clpt.2013.229.
- CPIc: Genes-Drugs. Dostupné z: <https://cpicpgx.org/genes-drugs/>, vyhledáno 14. 11. 2025.
- Deenen, M. J. – Meulendijks, D. – Cats, A., et al.: Upfront genotyping of DPYD\*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. *J Clin Oncol*, 2016, 34, s. 227–234, doi: 10.1200/JCO.2015.63.1325.
- Cortejoso, L. – García-González, X. – García, M. I., et al.: Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. *Pharmacogenomics*, 2016, 17, s. 979–984, doi: 10.2217/pgs-2016-0006.
- Turongkaravee, S. – Jittikoon, J. – Lukkunaprasit, T., et al.: A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. *Pharmacogenomics J*, 2021, 21, s. 296–307, doi: 10.1038/s41397-021-00208-w.

## Genomické testy jako nástroj racionální farmakoterapie v adjuvantní léčbě časného karcinomu prsu

doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

- Cardoso, F. – van't Veer, L. J. – Bogaerts, J., et al.: 70-gene signature as an aid to treatment decisions in early-stage breast cancer. *N Engl J Med*, 2016, 375, s. 717–729.
- Lopes Cardozo, J. M. N. – Drukker, C. A. – Rutgers, E. J. T., et al.: Outcome of patients with an ultralow-risk 70-gene signature in the MIN-DACT trial. *J Clin Oncol*, 2022, 40, s. 1335–1345.
- van't Veer, L. J. – Meershoek-Klein Kranenbarg, E. – Duijm-de Carpentier, M., et al.: Selection of patients with early-stage breast cancer for extended endocrine therapy: a secondary analysis of the IDEAL randomized clinical trial. *JAMA Netw Open*, 2024, 7, e2447530.
- Ward, S. – Scope, A. – Rafia, R.: Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. *Health Technol Assess*, 2013, 17, s. 1–302.
- Haan, J. C. – Bhaskaran, R. – Ellappalayam, A., et al.: MammaPrint and Blueprint comprehensively capture the cancer hallmarks in early-stage breast cancer patients. *Genes Chromosomes Cancer*, 2022, 61, s. 148–160.
- Blumencranz, P. – Habibi, M. – Shivers, S., et al.: The predictive utility of MammaPrint and Blueprint in identifying patients with locally advanced breast cancer who are most likely to have nodal downstaging and a pathologic complete response after neoadjuvant chemotherapy. *Ann Surg Oncol*, 2023, 30, s. 8353–8361.
- NCNN. Breast Cancer Screening and Diagnosis. Dostupné z: <https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1421>, vyhledáno 23. 10. 2025.
- ESMO. Multigene Sequencing in Breast Cancer: ESMO Biomarker Factsheet. Dostupné z: <https://oncologypro.esmo.org/publications/esmo-factsheets-on-biomarkers/multigene-sequencing-in-breast-cancer>, vyhledáno 23. 10. 2025.

## Terapeutický potenciál Ginkgo biloba: od mechanismu účinku po standardizaci produktů

PharmDr. Marek Lapka, Ph.D Ústav farmakologie, 3. LF UK, Praha

- Liu, X. G. – Lu, X. – Gao, W., et al.: Structure, synthesis, biosynthesis, and activity of the characteristic compounds from Ginkgo biloba L. *Nat Prod Rep*, 2022, 39, s. 474–511.
- Barkats, M. – Venault, P. – Christen, Y., et al.: Effect of long-term treatment with Egb 761 on age-dependent structural changes in the hippocampus of three inbred mouse strains. *Life Sci*, 1994, 56, s. 213–222.
- Lejri, I. – Vukalović, I. – Grimm, A., et al.: Proanthocyanidins from Ginkgo extract Egb 761\* improve bioenergetics and stimulate neurite outgrowth in vitro. *Front Pharmacol*, 2025, 16, 1495997.
- Guo, J. – Tang, W. – Tang, W., et al.: Research progress on the types, functions, biosynthesis, and metabolic regulation of ginkgo terpenoids. *Plant Physiol Biochem*, 2024, 212, 108754.
- Morató, X. – Tartari, J. P. – Pytel, V., et al.: Pharmacodynamic and clinical effects of Ginkgo biloba extract Egb 761 and its phytochemical components in Alzheimer's disease. *J Alzheimers Dis*, 2024, 101(s1), s. S285–S298.
- Guo, J. – Tang, W. – Tang, W., et al.: Research progress on the types, functions, biosynthesis, and metabolic regulation of ginkgo terpenoids. *Plant Physiology and Biochemistry*, 2024, 212, 108754.
- Wang, L. T. – Huang, H. – Chang, Y. H., et al.: Biflavonoids from Ginkgo biloba leaves as a novel anti-atherosclerotic candidate: Inhibition potency and mechanistic analysis. *Phytomedicine*, 2022, 102, 154053.
- Marcilhac, A. – Dakine, N. – Bourhim, N., et al.: Effect of chronic administration of Ginkgo biloba extract or Ginkgolide on the hypothalamic-pituitary-adrenal axis in the rat. *Life Sci*, 1998, 62, s. 2329–2340.
- Chen, X. – Salwinski, S. – Lee, T. F.: Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. *Clin Exp Pharmacol Physiol*, 1997, 24, s. 958–959.
- Maerz, S. – Liu, C. H. – Guo, W., et al.: Anti-ischaemic effects of bilobalide on neonatal rat cardiomyocytes and the involvement of the platelet-activating factor receptor. *Biosci Rep*, 2011, 31, s. 439–447.
- Köse, K. – Doğan, P.: Lipoperoxidation induced by hydrogen peroxide in human erythrocyte membranes. 1. Protective effect of Ginkgo biloba extract (Egb 761). *J Int Med Res*, 1995, 23, s. 1–8.
- Stern, R. G. – Mohs, R. C. – Davidson, M., et al.: A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. *Am J Psychiatry*, 1994, 151, s. 390–396.
- Semlitsch, H. V. – Anderer, P. – Saletu, B., et al.: Cognitive psychophysiology in nootropic drug research: effects of Ginkgo biloba on event-related potentials (P300) in age-associated memory impairment. *Pharmacopsychiatry*, 1995, 28, s. 134–142.
- Rai, G. S. – Shovlin, C. – Wesnes, K. A.: A double-blind, placebo controlled study of Ginkgo biloba extract (tanakan) in elderly outpatients with mild to moderate memory impairment. *Curr Med Res Opin*, 1991, 12, s. 350–355.
- Le Bars, P. L. – Katz, M. M. – Berman, N., et al.: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American Egb Study Group. *JAMA*, 1997, 278, s. 1327–1332.
- Schneider, L. S. – DeKosky, S. T. – Farlow, M. R., et al.: A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. *Curr Alzheimer Res*, 2005, 2, s. 541–551.
- Herrschaf, H. – Nacu, A. – Likhachev, S., et al.: Ginkgo biloba extract Egb 761\* in dementia with neuropsychiatric features: A randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. *J Psychiatr Res*, 2012, 46, s. 716–723.
- Kandiah, N. – Ong, P. A. – Yuda, T., et al.: Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, Egb 761\*. *CNS Neurosci Ther*, 2019, 25, s. 288–298.
- Gauthier, S. – Schlaefke, S.: Efficacy and tolerability of Ginkgo biloba extract Egb 761\* in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. *Clin Interv Aging*, 2014, 9, s. 2065–2077.
- Hashiguchi, M. – Ohta, Y. – Shimizu, M., et al.: Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. *J Pharm Health Care Sci*, 2015, 1, s. 14.
- Von Gunten, A. – Schlaefke, S. – Überla, K.: Efficacy of Ginkgo biloba extract Egb 761\* in dementia with behavioural and psychological symptoms: A systematic review. *World J Biol Psychiatry*, 2016, 17, s. 622–633.
- Vellas, B. – Coley, N. – Ousset, P. J., et al.: Long-term use of standardized ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. *Lancet Neurol*, 2012, 11, s. 851–859.
- DeKosky, S. T. – Williamson, J. D. – Fitzpatrick, A. L., et al.: Ginkgo biloba for prevention of dementia: a randomized controlled trial. *JAMA*, 2008, 300, s. 2253–2262.
- Scherrer, B. – Andrieu, S. – Ousset, P. J., et al.: Analysing time to event data in dementia prevention trials: the example of the GuidAge study of Egb761. *J Nutr Health Aging*, 2015, 19, s. 1009–1011.
- Ihl, R. – Frölich, L. – Winblad, B., et al.: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of Alzheimer's disease and other dementias. *World J Biol Psychiatry*, 2011, 12, s. 2–32.
- Vaskulární demence. Dostupné z: <https://postupy-pecce.psychiatrie.cz/specialni-psychiatrie/demence/vaskularni-demence>, vyhledáno 16. 11. 2025.
- Rusina, R. – Vaňková, H.: *Alzheimerova nemoc a jiné kognitivní nemoci*. Praha, Maxdorf Jessenius, 2024.
- Matějková, A. – Bartoš, A. – Býma, S., et al.: *Demence: doporučený diagnostický a terapeutický postup pro všeobecné praktické lékaře 2024*. Praha, Centrum doporučených postupů pro praktické lékaře, Společnost všeobecného lékařství ČLS JEP, 2024.
- Schubert, H. – Halama, P.: Depressive episode primarily unresponsive to therapy in elderly patients: Efficacy of Ginkgo biloba (Egb 761) in combination with antidepressants. *Geriatr Forsch*, 1993, 3, s. 45–53.
- Lingaerde, O. – Foreland, A. R. – Magnusson, A.: Can winter depression be prevented by Ginkgo biloba extract? A placebo-controlled trial. *Acta Psychiatr Scand*, 1999, 100, s. 62–66.
- Cohen, A. J. – Bartlik, B.: Ginkgo biloba for antidepressant-induced sexual dysfunction. *J Sex Marital Ther*, 1998, 24, s. 139–143.
- Wheatley, D.: Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. *Hum Psychopharmacol*, 2004, 19, s. 545–548.
- Nicolai, S. P. A. – Kruidenier, L. M. – Bendermacher, B. L. W., et al.: Ginkgo biloba for intermittent claudication. *Cochrane Database Syst Rev*, 2013, 2013, CD006888.
- Hirsch, A. T. – Haskal, Z. J. – Hertzler, N. R., et al.: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease); endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute;

- Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation*, 2006, 113, s. e463–e654.
- 35 **Haguenauer, J. P. – Cantenot, F. – Koskas, H., et al.:** Treatment of equilibrium disorders with Ginkgo biloba extract. A multicenter double-blind drug vs. placebo study. *Presse Med*, 1986, 15, s. 1569–1572.
- 36 **Quaranta, L. – Bettelli, S. – Uva, M. G., et al.:** Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. *Ophthalmology*, 2003, 110, s. 359–362.
- 37 **Evans, J. R.:** Ginkgo biloba extract for age-related macular degeneration. *Cochrane Database Syst Rev*, 2013, 2013, CD001775.
- 38 **Bent, S. – Goldberg, H. – Padula, A., et al.:** Spontaneous bleeding associated with Ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. *J Gen Intern Med*, 2005, 20, s. 657–661.
- 39 **Rosenblatt, M. – Mindel, J.:** Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. *N Engl J Med*, 1997, 336, s. 1108.
- 40 **Kellermann, A. J. – Kloft, C.:** Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. *Pharmacotherapy*, 2011, 31, s. 490–502.
- 41 **Siegers, C. P.:** Cytotoxicity of alkylphenols from Ginkgo biloba. *Phyto-medicine*, 1999, 6, s. 281–283.
- 42 **Gregory, P. J.:** Seizure associated with Ginkgo biloba? *Ann Intern Med*, 2001, 134, s. 344.
- 43 **Ramassamy, C. – Christen, Y. – Clostre, F., et al.:** The Ginkgo biloba extract, EGb761, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies. *J Pharm Pharmacol*, 1992, 44, s. 943–945.
- 44 **Yasui-Furukori, N. – Furukori, H. – Kaneda, A., et al.:** The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. *J Clin Pharmacol*, 2004, 44, s. 538–542.
- 45 **O'Hara, M. – Kiefer, D. – Farrell, K., et al.:** A review of 12 commonly used medicinal herbs. *Arch Fam Med*, 1998, 7, s. 523–536.
- 46 **Cohen, P. A.:** Assessing supplement safety—the FDA's controversial proposal. *N Engl J Med*, 2012, 366, s. 389–391.
- 47 **Germer, S. – Ritter, T. – Wurglics, M.:** Substantial differences in proanthocyanidin contents among Ginkgo biloba leaf extracts in herbal medicinal products obtained from the German market. *Planta Med*, 2024, 90, s. 1040–1047.

## Superoxidovaný roztok kyseliny chlorné v léčbě ran: komplexní monografie se zvláštním důrazem na zdravotnický prostředek Aqvitox-D roztok a gel

doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

- 1 **Winterbourn, C. C.:** Reconciling the chemistry and biology of reactive oxygen species. *Nat Chem Biol*, 2008, 4, s. 278–286.
- 2 **Ulfing, A. – Leichert, L. I.:** The effects of neutrophil-generated hypochlorous acid and other hypohalous acids on host and pathogens. *Cell Mol Life Sci*, 2021, 78, s. 385–414.
- 3 **Block, M. S. – Rowan, B. G.:** Hypochlorous acid: a review. *J Oral Maxillofac Surg*, 2020, 78, s. 1461–1466.
- 4 **Kiamco, M. M. – Zmuda, H. M. – Mohamed, A., et al.:** Hypochlorous-acid-generating electrochemical scaffold for treatment of wound biofilms. *Sci Rep*, 2019, 9, s. 2683.
- 5 **Méndez-Durán, A.:** Efficacy and safety of the use of superoxidized solution in the prevention of dialysis-related infections. *Dial Transpl*, 2013, 34, s. 160–165.
- 6 **Day, A. – Alkhalil, A. – Carney, B. C., et al.:** Disruption of biofilms and neutralization of bacteria using hypochlorous acid solution: an in vivo and in vitro evaluation. *Adv Skin Wound Care*, 2017, 30, s. 543–551.
- 7 **Khan, M. – Khan, S. – Verma, A., et al.:** Evaluation of pre-operative peritoneal lavage by superoxidized solution in peritonitis. *Middle East Journal of Internal Medicine*, 2009, 2, s. 15–35.
- 8 **Mohd, A. R. – Ghani, M. K. – Awang, R. R., et al.:** Dermacyn irrigation in reducing infection of a median sternotomy wound. *Heart Surg Forum*, 2010, 13, s. E228–E232.
- 9 **Garg, P. – Garg, A. – Kumar, A., et al.:** Evaluation of intraoperative peritoneal lavage with super-oxidized solution and normal saline in acute peritonitis. *Archives of International Surgery*, 2013, 3, s. 43.
- 10 **Mekkawy, M. M. – Kamal, A.:** A randomized clinical trial: the efficacy of hypochlorous acid on septic traumatic wound. *Journal of Education and Practice*, 2014, 5, s. 89–100.
- 11 **Prabhakar, K. – Purushotham, G. – Uma, K.:** Comparison of super-oxidized solution versus povidone iodine in management of infected diabetic ulcers: our experience. *IAAIM*, 2016, 3, s. 151–158.
- 12 **Piaggese, A. – Goretti, C. – Mazzurco, S., et al.:** A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot. *Int J Low Extrem Wounds*, 2010, 9, s. 10–15.
- 13 **Suri, A.:** The effectiveness of stable pH-neutral super-oxidized solution for the treatment of diabetic foot wounds. Diabetic Foot Global Conference, Los Angeles, CA, 2008.
- 14 **Martínez-De Jesús, F. R. – Ramos-De la Medina, A., Remes-Troche, J. M., et al.:** Efficacy and safety of neutral pH superoxidized solution in severe diabetic foot infections. *Int Wound J*, 2007, 4, s. 353–362.
- 15 **Hadi, S. F. – Khaliq, T. – Bilal, N., et al.:** Treating infected diabetic wounds with superoxidized water as anti-septic agent: a preliminary experience. *Journal of the College of Physicians and Surgeons–Pakistan*, 2007, 17, s. 740–743.
- 16 **Bongiovanni, Ch. M.:** Effects of hypochlorous acid solutions on venous leg ulcers (VLU): Experience with 1249 VLUs in 897 patients. *Journal of the American College of Clinical Wound Specialists*, 2016, 6, s. 32–37.
- 17 **Sakarya, S. – Gunay, N. – Karakulak, M., et al.:** Hypochlorous Acid: an ideal wound care agent with powerful microbicidal, antibiofilm, and wound healing potency. *Wounds*, 2014, 26, s. 342–350.
- 18 **Gold, M. H. – Andriessen, A. – Bhatia, A. C., et al.:** Topical stabilized hypochlorous acid: The future gold standard for wound care and scar management in dermatologic and plastic surgery procedures. *Journal of Cosmetic Dermatology*, 2020, 19, s. 270–277.
- 19 Data on File. Aqvitox Technology, s. r. o.